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Abstract
Background:  Although various hematologic abnormalities are seen in tuberculosis, immune
thrombocytopenic purpura is a rare event.
Case Presentation: We report a case of a 29 year-old male who was presented with immune
thrombocytopenia-induced hemoptysis, macroscopic hematuria and generalized petechiae. The
patient was found to have clinical, microbiological and radiological evidence of active pulmonary
tuberculosis. The immune thrombocytopenic purpura was successfully treated with anti-
tuberculous drugs combined with corticosteroids and high dose immune globulin therapy.
Conclusion: Immune thrombocytopenic purpura can be one of the hematological manifestations
of tuberculosis which has a global prevalence with increasing incidence secondary to HIV infection.
Background
During the past 2 decades, tuberculosis -both pulmonary
and extrapulmonary- has re-emerged as a major health
problem worldwide. Hematologic abnormalities have
been described in association with mycobacterial infec-
tions for almost 100 years. Patients with both pulmonary
and extrapulmonary tuberculosis (TB) may demonstrate
peripheral blood abnormalities and findings may be min-
imal or profound [1,2]. A comprehensive review of the lit-
erature reveals a few case reports documenting
tuberculosis as a cause of severe hematologic conditions
such as hemophagocytic syndrome, thrombotic thrombo-
cytopenic purpura and immune hemolytic anemia.
Immune thrombocytopenic purpura (immune TP) associ-
ated with tuberculosis is exceedingly rare event. We report
the case of immune TP associated with tuberculosis that
was presented with severe hemorrhagic diathesis.
Case Presentation
A 29-year-old previously healthy immigrant male patient
from Kazakhstan was admitted to hospital with new-
onset severe hemoptysis, macroscopic hematuria and
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extensive cutaneous petechiae on lower extremities. He
appeared ill and poorly nourished. The patient was ori-
ented and well cooperated, and there was no previous his-
tory of hematologic or liver or another disease and recent
medication. He presented with unexplained weight loss of
2 months duration along with intermittent fever, night
sweats and cough. The physical examination revealed a
blood pressure of 100/70 mm/Hg, pulse 100/min, a tem-
perature 37.2°C, extensive cutaneous petechiae on lower
extremities, hemorrhagic bulla on tongue and on mucosa
of oral cavity, and amphoric soufflé on apex of right chest.
No organomegaly or lymphadenomegaly or evidence of
another disease such as chronic liver disease was detecta-
ble. The initial complete blood count revealed a white
blood cell 25.1 × 109/l (58% neutrophils, 29% bants, 9%
lymphocytes and 4% monocytes), hemoglobin 11.2 gr/dl,
hematocrit 36%, MCV 84 fl, reticulocytes 1% and platelet
count 7.6 × 109/l. Erythrocyte sedimentation rate was 110
mm/h. A peripheral smear was remarkable for a paucity of
platelets. Coagulation profile [prothrombin time (PT),
activated-partial thromboplastin time (aPTT), fibrin deg-
radation products (FDP)] were normal. A bone marrow
aspiration demonstrated hypercellularity of all cell lines
with normal maturation of myeloid and erythroid precur-
sors. Megakaryocytes were increased in number with nor-
mal morphology. On bone marrow aspiration
hemophagocytosis was not observed. A chest X-ray (Fig-
ure 1) and computed tomography (CT) (Figure 2) demon-
strated bilateral patchy infiltrates and walled cavities on
left and right upper lobes. Acid-fast bacilli were strongly
positive in sputum (Figure 3). Bone marrow aspirate and
urine for acid-fast bacilli were negative. Sputum culture
yielded mycobacterium tuberculosis complex. The follow-
ing laboratory studies were normal or negative: biochem-
ical tests (glucose, urea, creatinine, uric acid, sodium,
potassium, calcium, chloride, phosphorus, aspartate ami-
notransferase, alanine aminotransferase, alkaline phos-
phatase, lactate dehydrogenase, bilirubin, total protein
and albumin), rheumatoid factor, anti-nuclear antibody,
anti-platelet specific antibodies, Coomb's tests, HIV, hep-
atitis B and C virus, blood culture, bone marrow aspirate
culture and abdominopelvic CT. No granuloma or hemo-
phagocytosis was detected on bone marrow biopsy. The
patient was started on rifampin 10 mg/kg/d, isoniazid 5
mg/kg/d, ethambutol 25 mg/kg/d, pyrazinamide 40 mg/
kg/d, pyridoxine 75 mg/d and intravenous immune glob-
ulin (IVIg) 1 g/kg/d given for 2 days. On day 2 of hospi-
talization and treatment of anti-tuberculous therapy
prednisolone 1 mg/kg/d was added. On day 8, platelet
counts started to increase and on day 12 of the treatment
it reached to 187 × 109/l level. Patient improved on day 10
and he did not have any complaints on day 14; at time of
discharge. He received a total of 6 red blood cell (RBC)
units throughout hospitalization. During his hospitaliza-
tion findings of hemolysis or gastrointestinal bleeding
and massive bleeding in another site except hematuria
and hemoptysis were not established. A complete blood
count at discharge demonstrated a WBC 17 × 109/l, Hb
9.6 g/dl, and platelet count 310 × 109/l (Table 1). Corti-
costeroids were discontinued on day 14 of therapy and
the patient was discharged and recurrent thrombocytope-
nia was not established after withdrawal of corticosteroid
therapy. Ninety days after discharge, the patient was well
with a platelet count of 300 × 109/l (Table 1) and he had
no side effect thought to be secondary to anti-tuberculous
drugs.
Discussion
Tuberculosis differs from many other infectious maladies
in having particular social and geographic distributions.
The disease was under control in developed nations and
getting under control in developing nations, until the
emergence of HIV infection and the advent of multidrug
resistant strains of mycobacteria [3-5]. Various hemato-
logic abnormalities such as anemia, leukocytosis, mono-
cytosis, lymphopenia, leucopenia, thrombocytopenia,
thrombocytosis, leukemoid reactions and pancytopenia
have been seen in tuberculosis [1,2], but severe thrombo-
cytopenia and presenting of tuberculosis as immune
thrombocytopenic purpura is extremely rare and there are
a few reports about tuberculosis induced immune
thrombocytopenic purpura published in the world litera-
ture [6-10].
Anteroposterior chest radiograph showing cavitary lesions in  both lungs Figure 1
Anteroposterior chest radiograph showing cavitary lesions in 
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The case that we report could be confused by coincidental
presentation of adult idiopathic thrombocytopenic pur-
pura and tuberculosis, by drug-induced thrombocytope-
nia, thrombotic thrombocytopenic purpura (TTP)-
hemolytic uremic syndrome (HUS), hemophagocytic syn-
drome and disseminated intravascular coagulation (DIC)
associated with TB. Idiopathic thrombocytopenic purpura
(ITP, also known as primary immune thrombocytopenic
purpura) is an acquired disease of children and adults
defined as isolated thrombocytopenia with no clinically
apparent associated conditions or other causes of throm-
bocytopenia. Adult ITP typically has an insidious onset
with long-lasting histories of purpura (thrombocytopenia
for >6 months) and spontaneous remission is uncommon
and is likely to be incomplete [11-13]. Steroids are the
conventional first line therapy for adult ITP. Platelets
counts increase within one week in responding patients
and usually reach peak values by two to four weeks. How-
ever, in most patients, thrombocytopenia recurs when
steroids are tapered or discontinued. Also in adult, IVIg is
used when clinical situations require a transient increase
of the platelet count and a typical response is an increase
Table 1: Characteristics of patient
Day Hb (g/dl) Hct (%) WBC (×109)P l t  ( × 1 0 9) Treatment
1 1 1 . 23 6 2 5 . 17 . 6 A n t i - t b c  d r u g s  +  I V I g
2 8 25 23.1 9.6 Anti-tbc drugs + IVIg+Pred+1 RBC Susp
3 8.1 25 22.7 17.7 Anti-tbc drugs+ Pred+ 2 RBC Susp
4 1 0 . 33 3 2 0 . 61 5 . 1A n t i - t b c  d r u g s +  P r e d
5 8.6 27 24.5 12.3 Anti-tbc drugs+ Pred+ 1 RBC Susp
6 8.2 24 25.4 4.0 Anti-tbc drugs + Pred + 2 RBC Susp
7 1 0 . 12 9 2 0 . 64 . 7 A n t i - t b c  d r u g s +  P r e d
8 1 0 . 53 2 1 7 . 72 0 . 2A n t i - t b c  d r u g s +  P r e d
9 9.9 31 15.8 36.6 Anti-tbc drugs+ Pred
10 10.3 33 18 59 Anti-tbc drugs+ Pred
11 9.4 28 14 100 Anti-tbc drugs+ Pred
12 9.7 28 18.1 187 Anti-tbc drugs+ Pred
13 9.1 26 15.2 324 Anti-tbc drugs+ Pred
14 9.6 28 17 310 Anti-tbc drugs
45 12.3 37 15.5 304 Anti-tbc drugs
90 14 43 11 300 Anti-tbc drugs
Abbreviations: Anti-tbc drugs: anti-tuberculous drugs, Pred: Prednisolone, Susp: Suspension
CT showing cavitary lesions in both lungs Figure 2
CT showing cavitary lesions in both lungs
Sputum showing positivity of acid-fast bacilli Figure 3
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in platelet count several days after the infusions are initi-
ated and return to the pretreatment level within several
weeks [11,13]. In our case, we excluded the adult ITP not
only by basing on standard criteria [12], but with response
to steroids and IVIg therapy since thrombocytopenia did
not recur after withdrawal of prednisone and IVIg therapy.
Also we excluded other causes of thrombocytopenia such
as hemophagocytic syndrome, TTP, combined autoim-
mune cytopenias with history, clinical and laboratory
findings, and examination of bone marrow aspiration and
biopsy that were described in case presentation.
Several factors are known to cause bleeding in association
with infections, of which thrombocytopenia is the most
common. The etiology of thrombocytopenia in most
cases appears to be increased destruction of platelets such
as due to DIC or septicemia without evidence of DIC or
platelet adherence to damaged vascular surfaces or direct
platelet toxicity caused by the microorganism or involve-
ment of bone marrow. Adult acute immune thrombocyto-
penic purpura is defined as a bleeding disorder in
otherwise healthy person caused by transient destruction
of platelets. Although the most important therapy for
infection-related thrombocytopenia is that directed at the
underlying infection, treatment decisions for immune
thrombocytopenic purpura remain controversial and may
include single or combination therapy with corticoster-
oids, intravenous immunoglobulin (IVIg) according to
degree of thrombocytopenia or hemorrhage [11,14]. The
case that we reported was presented with symptoms of
phthisis lasting for more than 2 months and severe hemo-
ptysis, macroscopic hematuria and extensive cutaneous
bleeding findings lasting for one week. Based on the clin-
ical, radiological (X-ray and CT of chest) findings, demon-
stration of positivity of acid-fast bacilli in sputum and
with exclusion of other causes of thrombocytopenia,
immune thrombocytopenic purpura due to pulmonary
tuberculosis was diagnosed. We applied anti-tuberculous
therapy combined with corticosteroids and IVIg because
of severe thrombocytopenia and severe hemorrhagic dia-
thesis. Clinically, steroids are known to ameliorate the
purpuric bleeding in patients before the platelet count
actually increases. The early effect is due to decrease of vas-
cular permeability. The effect of the steroids in the throm-
bocytopenia is probably complex and it is late effect. The
mechanism of action of IVIg is unclear, but studies suggest
blockage of the Fc receptors of the reticuloendothelial
cells and suppression of antibody production and binding
which may be a result of anti-idiotype antibodies that
bind antiplatelet antibodies and modulate the immune
response [14]. In our case, corticosteroids were discontin-
ued on day 14 of therapy and the patient was discharged
and recurrent thrombocytopenia was not established after
withdrawal of corticosteroid therapy. These observations
suggest that tuberculosis is the cause of thrombocytopenia
in our patient. He received a total of 6 RBC units through-
out hospitalization. He did not have findings of Coomb's
positive or negative hemolytic anemia or microangio-
pathic hemolytic anemia, hemophagocytic syndrome,
gastrointestinal bleeding and massive bleeding to thoracic
cavity. But he had severe hemoptysis and macroscopic
hematuria. Ninety days after discharge, the patient was in
well health with a platelet count of 300 × 109/l and he had
no side effect thought to be secondary to anti-tuberculous
drugs [15,16]. The patient is still in our follow-up without
relapsing of thrombocytopenia.
In conclusion, since the incidence of tuberculosis is cur-
rently increasing in worldwide countries and it may
present with different hematologic manifestations, in case
of immune thrombocytopenic purpura tuberculosis
should also be recalled. Finally, further studies are needed
in order to fully characterize the pathophysiology and
immunological abnormalities in tuberculosis-related
immune thrombocytopenic purpura.
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